Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

被引：7

作者：

Yu, E. ^{[1
]}

Piulats, J. M. ^{[2
]}

Gravis, G. ^{[3
]}

Fong, P. C. C. ^{[4
]}

Todenhoefer, T. ^{[5
]}

Laguerre, B. ^{[6
]}

Arranz Arija, J. A. ^{[7
]}

Oudard, S. ^{[8
]}

Massard, C. ^{[9
,10
]}

Stoeckle, M. ^{[11
]}

Nordquist, L. T. ^{[12
]}

Carles, J. ^{[13
]}

Kolinsky, M. P. ^{[14
]}

Augustin, M. ^{[15
]}

Gurney, H. ^{[16
,17
]}

Tafreshi, A. ^{[18
]}

Li, X. T. ^{[19
]}

Poehlein, C. H. ^{[19
]}

Schloss, C. ^{[19
]}

de Bono, J. S. ^{[20
]}

机构：

[1] Univ Washington, Med Oncol, Seattle, WA 98195 USA

[2] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[3] Inst Paoli Calmettes, Med Oncol, Paris, France

[4] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[5] Studienpraxis Urol, Urol, Nuertingen, Germany

[6] Ctr Eugene Marquis, Med Oncol, Rennes, France

[7] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[8] Hop Europeen Georges Pompidou, Med Oncol, Paris, France

[9] Gustave Roussy Canc Campus, Med Oncol, Villejuif, France

[10] Paris Sud Univ, Villejuif, France

[11] Saarland Univ Hosp, Urol, Homburg, Germany

[12] Urol Canc Ctr, GU Res Network, Med Oncol, Omaha, NE USA

[13] Vall dHebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain

[14] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Paracelsus Med Univ, Urol, Nurnberg, Germany

[16] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[17] Macquarie Univ Hosp, Sydney, NSW, Australia

[18] Univ Wollongong, Med Oncol, Wollongong, NSW, Australia

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Royal Marsden NHS Fdn Trust, Med Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

612P

引用

页码：S652 / S653

页数：2